Shares of Myriad Genetics (MYGN) continued their downward spiral in pre-market trading on Wednesday, plunging 17.47% following the release of disappointing first-quarter financial results and a weak full-year outlook. This pre-market decline comes on the heels of a 13.34% drop in the previous trading session, reflecting growing investor concerns about the genetic testing company's financial health and future prospects.
Myriad Genetics reported a substantial operating loss of $29 million for Q1, with revenue falling 3.1% to $195.90 million, missing analyst expectations of $200.56 million. The company's outlook for fiscal year 2025 further dampened investor sentiment, with forecasted revenue ranging from $807 million to $823 million and adjusted earnings per share between a loss of $0.02 and a profit of $0.02.
Despite maintaining a gross margin of 69%, Myriad Genetics' high operating expenses, totaling $163.2 million ($140.6 million on an adjusted basis), significantly impacted its bottom line. The company's adjusted operating loss stood at $5.5 million for the quarter. The continued stock sell-off in pre-market trading underscores growing apprehension about Myriad Genetics' ability to achieve profitability and sustain growth in the competitive genetic testing industry, prompting investors to reassess their positions in the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.